Long-Lasting Responses After Discontinuation of Nivolumab Treatment for Reasons Other Than Tumor Progression in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Cancer Communications - United Kingdom
doi 10.1186/s40880-019-0423-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

179P: Nivolumab Monotherapy in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice in a Spanish Center

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

OncoImmunology
OncologyAllergyImmunology
2018English

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Treatment Results Including More Than Third-Line Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2010English

MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Factors Associated With Early Progression and Grade 3–4 Toxicity in Patients With Advanced Non-Small-Cell Lung Cancers Treated With Nivolumab

PLoS ONE
Multidisciplinary
2018English

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2018English

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

JAMA Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy